681
+3.65%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Almado
Its shares trade on Tokyo Stock Exchange under the ticker 4932.T. It has been listed since 24 June 2021. In the fiscal year to 31 March 2026, it reported revenue of ¥10.12bn and net income of ¥518.4m. At that date it held total assets of ¥4.54bn and shareholders' equity of ¥1.82bn.
Almado, Inc. develops and distributes cosmetics and supplements. The company is headquartered in Chuo-Ku, Tokyo-To. The company went IPO on 2021-06-24. All food and cosmetics production are outsourced. The firm operates the Eggshell Membrane Healthcare business segment. Sales channels include television (TV) shopping sales, external indirect sales and in-house direct sales. In TV shopping sales, the Company introduces eggshell membrane foods and eggshell membrane cosmetics through QVC TV shopping, a TV shopping specialty channel. The main products are the Ode series of cosmetics and TO-II of food. External indirect sales include sales of original equipment manufacturing (OEM) products and wholesale sales. In-house direct sales receive orders directly from end consumers through their own e-commerce sites and other companies' e-commerce sites. Major products include the CELLULA series of cosmetics.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Consumer Staples
- Industry
- Personal Care Products
- Listed since
- 24 Jun 2021
- Employees
- 41
- Website
- almado.co.jp ↗
Leadership
Pay as last reported
- Toshikazu AranishiPresident & Representative Director, since 2017
- Hiromasa WarabiDirector, Head-Administration & Planning, since 2018
- Yuji HasebeDirector, Head-Development & Manufacturing, since 2006
- Shiro HoshinaManaging Director & Head-Sales, since 2014
- Toshikazu AranishiPresident & Representative Director, since 2017
- Hiromasa WarabiDirector, Head-Administration & Planning, since 2019
- Hiroyuki Owada, CPAIndependent Outside Director, since 2019
- Shiro HoshinaManaging Director & Head-Sales, since 2015
- Yuji HasebeDirector, Head-Development & Manufacturing, since 2015
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company has a clear business segment focused on Eggshell Membrane Healthcare.
- Operates multiple sales channels including TV shopping, OEM, and direct e-commerce.
- Maintains a dedicated website for direct consumer engagement.
Weaknesses
- All production is outsourced, which may lead to quality control challenges.
- Limited employee count of 41 may restrict operational capacity.
- Reliance on a single product line (Ode and CELLULA series) could increase market vulnerability.
Opportunities
- Expansion of TV shopping sales through QVC channel could increase market reach.
- Potential for growth in OEM and wholesale sales channels.
- Increasing demand for natural health products could benefit Eggshell Membrane Healthcare segment.
Threats
- Dependence on outsourced production may lead to supply chain disruptions.
- Competition in the cosmetics and supplement industry could impact market share.
- Economic downturns might reduce consumer spending on non-essential products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.